GenMark Diagnostics, Inc (NASDAQ:GNMK) price target raised to $10.00 by Canaccord Genuity

ME Staff
-
0

Analyst Ratings For GenMark Diagnostics, Inc (NASDAQ:GNMK)

Today, Canaccord Genuity raised its price target on GenMark Diagnostics, Inc (NASDAQ:GNMK) to $10.00 per share.

There are 5 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on GenMark Diagnostics, Inc (NASDAQ:GNMK) is Buy with a consensus target price of $11.00 per share, a potential 68.71% upside.

Some recent analyst ratings include

  • 7/31/2018-Needham & Company LLC Reiterated Rating of Buy.
  • 11/3/2017-Cowen Reiterated Rating of Buy.
  • 11/3/2017-Raymond James Reiterated Rating of Outperform .
  • 9/18/2017-Bank of America initiated coverage with a Buy rating.


  • On 5/23/2018 Hany Massarany, Insider, sold 4,168 with an average share price of $6.88 per share and the total transaction amounting to $28,675.84.
  • On 5/23/2018 Michael Gleeson, SVP, sold 984 with an average share price of $6.88 per share and the total transaction amounting to $6,769.92.
  • On 5/23/2018 Scott Mendel, CFO, sold 1,312 with an average share price of $6.88 per share and the total transaction amounting to $9,026.56.
  • On 5/21/2018 Hany Massarany, Insider, sold 5,459 with an average share price of $6.91 per share and the total transaction amounting to $37,721.69.
  • On 5/21/2018 Michael Gleeson, SVP, sold 1,764 with an average share price of $6.91 per share and the total transaction amounting to $12,189.24.
  • On 5/21/2018 Scott Mendel, CFO, sold 1,904 with an average share price of $6.91 per share and the total transaction amounting to $13,156.64.
  • On 5/18/2018 Jennifer Anne Williams, SVP, sold 23,688 with an average share price of $6.90 per share and the total transaction amounting to $163,447.20.

About GenMark Diagnostics, Inc (NASDAQ:GNMK)
GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company offers XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges. It also provides diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, thrombophilia risk test, a warfarin sensitivity test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test. The company sells its products through direct sales and technically specialized service organization in the United States and Europe. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California.

Recent Trading Activity for GenMark Diagnostics, Inc (NASDAQ:GNMK)
Shares of GenMark Diagnostics, Inc closed the previous trading session at 6,50 +0,46 7,62 % with 6.04 shares trading hands.